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Genomic lesions associated with a different clinical outcome
in diffuse large B-Cell lymphoma treated with R-CHOP-21
Summary
Despite recent therapeutic improvements, the clinical course of diffuse large
B-cell lymphoma (DLBCL) still differs considerably among patients. We
conducted this retrospective multi-centre study to evaluate the impact of
genomic aberrations detected using a high-density genome wide-single
nucleotide polymorphism-based array on clinical outcome in a population of
DLBCL patients treated with R-CHOP-21 (rituximab, cyclophosphamide,
doxorubicine, vincristine and prednisone repeated every 21 d). 166 DNA
samples were analysed using the GeneChip Human Mapping 250K NspI.
Genomic anomalies were analysed regarding their impact on the clinical
course of 124 patients treated with R-CHOP-21. Unsupervised clustering was
performed to identify genetically related subgroups of patients with different
clinical outcomes. Twenty recurrent genetic lesions showed an impact on the
clinical course. Loss of genomic material at 8p23.1 showed the strongest
statistical significance and was associated with additional aberrations, such as
17p- and 15q-. Unsupervised clustering identified five DLBCL clusters with
distinct genetic profiles, clinical characteristics and outcomes. Genetic
features and clusters, associated with a different outcome in patients
treated with R-CHOP, have been identified by arrayCGH.
Keywords: prognosis, lymphoma, comparative genomic hybridization,
microarray, hepatitis C virus.
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Non-Hodgkin lymphomas (NHLs) represent the fifth most
frequent cancer (Jemal et al, 2009). Diffuse large B-cell
lymphoma (DLBCL) constitutes the most common subtype,
accounting for 25–30% of adult NHLs in Western countries,
and is characterized by heterogeneous histopathological,
clinical and biological features (Armitage, 2007; Lenz & Staudt,
2010). DLBCL represents a potentially curable disease when
treated with R-CHOP-21 (rituximab, cyclophosphamide,
doxorubicine, vincristine and prednisone repeated every
21 d) for 6–8 cycles. Nevertheless, the progression-free survival
(PFS) in elderly patients is still below 55% and in younger
patients does not exceed 85%.
Gene expression profiling (GEP) patterns and genomic
aberrations have been identified to have an impact on the
clinical course of DLBCL patients treated with CHOP (Lenz
et al, 2008a; Lenz & Staudt, 2010). Differently from GEP data
(Lenz et al, 2008b), no information is available on the
prognostic impact of genomic aberrations detected using high
resolution single nucleotide polymorphism (SNP) array in
DLBCL patients treated with R-CHOP.
In this study, we analysed the impact of recurrent aberra-
tions revealed by a high-density genome wide SNP-based
array on clinical outcome in DLBCL patients treated with
R-CHOP-21.
Materials and methods
Tumour panel
DNA was extracted from 166 frozen tumour biopsies of
DLBCL, taken at diagnosis as previously described (Capello
et al, 2010; Rinaldi et al, 2010). Cases were selected for the
study based upon the availability of frozen material, and were
required to have a fraction of malignant cells in the
pathological specimen representing >70% of overall cellular-
ity as determined by morphological and immunophenotypic
studies. Cases of primary mediastinal large B-cell lymphoma,
human immunodeficiency virus-related DLBCL and post-
transplant DLBCL were excluded. Therapy was R-CHOP21 in
137 cases (13 with no follow-up data available) and other
than R-CHOP21 in 14 (four, R-CHOP14; two, CHOP; four
high-dose chemotherapy; four, other), and unknown in 15.
As previously reported (Capello et al, 2010; Rinaldi et al,
2010), the distinction of DLBCL cases in germinal centre
B-cell-like (GCB) or in non-GCB, was available in 110 cases:
assessed in 52 cases by immunohistochemistry according to
the algorithm of Hans et al (2004) (25 GCB, 27 non-GCB)
and in 58 by GEP (Lenz et al, 2008b) (31 GCB, 27 non-
GCB). All patients provided informed consent in accordance
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with the hospital’s institutional review board and the
Declaration of Helsinki. The study was approved by the
Bellinzona Ethics Committee.
SNP array-CGH analysis and data mining
DNA samples were analysed using the GeneChip Human
Mapping 250K NspI (Affymetrix, Santa Clara, CA, USA), as
previously described (Capello et al, 2010; Rinaldi et al, 2010).
Data acquisition was performed using the GeneChip operat-
ing software (GCOS, Affymetrix, Santa Clara, CA, USA)
version 1.4 and genotyping analysis software (GTYPE,
Affymetrix, Santa Clara, CA, USA) version 4.1. Genotype calls
were calculated using the BRLMM algorithm (Bayesian Robust
Linear Model with Mahalanobis distance classifier). Mapping
data for probes were derived from the National Center for
Biotechnology Information (NCBI) Human Genome Build 36,
as provided by Affymetrix. The modified Bayesian Piecewise
Regression (mBPCR)method (Rancoita et al, 2009) was used to
estimate the copy number (CN) starting from raw CN values
obtained with Affymetrix CNAT 4Æ01 using a Gaussian band-
width of 0 Kb and 46 Caucasian normal female samples of the
HapMap Project as reference samples. After normalization of
each profile to a median log2-ratio of zero, thresholds for loss
and gain defined as six times the median absolute deviation
symmetrically around zero with an associated P value lower
than <0Æ001 after Bonferroni multiple test correction. Loss of
heterozygosity (LOH) profiles were obtained applying the
method with haplotype correction for tumour-only LOH
inference available in the dchip software (Beroukhim et al,
2006) using as reference the 60 CEPH (Centre d’Etude du
Polymorphisme Humain) parents of the HapMap Project and
computing the allele A frequency from the data. Figure S1
shows examples of the genomic lesions with raw and inferred
CN, and LOH estimate. Frequency plots for DNA gains, DNA
losses and LOH were calculated from mBPCR segmented CN
data, thresholded for gain or loss or for LOH, without removing
known copy number variations (CNV). All the 166 DLBCL
profiles were used to identify the minimal recurrent alterations
that are supposed to contain loci relevant for the tumour,
following the algorithm developed by Lenz et al (2008a). Four
distinct types of minimal common regions (MCR) were
defined: short recurrent abnormality (SRA), long recurrent
abnormality (LRA), abnormal chromosome arm (ACA) and
abnormal whole chromosome (AWC). In MCR frequencies,
patients carrying a lesion contained in both an SRA and in an
LRA were counted for both types of MCR. For MCR occurring
in at least 15% of cases, differences in frequencies between
subgroups were evaluated using a Fisher’s exact test followed by
multiple test correction (MTC). MCRs were compared with the
Database of Genomic Variants (http://projects.tcag.ca/varia-
tion/): regions showing an overlap above 80% between probes
and known CNV were considered bona fide CNV.
In order to identify biological subgroups according to the
genetic profile, unsupervised clustering was performed using
the non-negative matrix factorization (NMF) algorithm on all
166 cases (Lee & Seung, 2001; Chigrinova et al, 2010). The best
rank was chosen based upon the cophenetic correlation for the
consensus matrix.
The Database for Annotation, Visualization and Integrated
Discovery (DAVID) 2008 web-accessible program (Huang da
et al, 2009) was used to map genes contained within MCR,
retrieved using the web-accessible Galaxy (http://galaxy.
psu.edu/) (Giardine et al, 2005), to KEGG and Biocarta
Pathways, and statistically examine the enrichment of gene
members for each pathway.
Raw data will be available at the NCBI Gene Expression
Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo) database.
Gene expression
Previously published gene expression data (Lenz et al, 2008b),
obtained using the affymetrix genechip U133 plus 2.0
(Affymetrix, Santa Clara, CA, USA), were available for 54/166
cases. CEL files were imported in Partek Genomics Suite 6Æ4
(Partek, St Louis, MO, USA). Signal intensities were normal-
ized by Partek RMA. Statistical differences were calculated by
analysis of variance (anova) analysis and the genes with a P
value <0Æ005 were analysed for enrichment of KEGG and
Biocarta pathways using DAVID 2008 web-accessible program
(Huang da et al, 2009).
To classify our samples according to the DLBCL consensus
clusters described by Monti et al (2005), we trained a Naive
Bayes classifier based on the 176 labelled samples from the
original publication and 2117 probe-sets using the ‘naiveBayes’
function in the ‘e1071’ R-package. Then, this classifier was
appliedonournormalizedGEPvalues to infer the best associated
cluster: ‘oxidative phosphorylation,’ (OxPhos), ‘B-cell receptor/
proliferation,’ (BCR) and ‘host response’ (HR) clusters.
Statistical analysis
Response to R-CHOP-21, overall survival (OS), PFS and
disease-free survival (DFS), defined according to the criteria of
Cheson et al (2007), were evaluated in the 124/166 cases
treated with R-CHOP21 and with available follow-up data.
Survival probabilities were plotted according to the Kaplan-
Meier method. The impact of the MCR on the clinical
outcome was determined with the log-rank test (Mantel &
Haenszel, 1959). To control false positive rate the Benjamini-
Hochberg-method (Q-value) was performed. Internal valida-
tion was quantified by calculating the Harrell concordance
index (C-index) (Harrell, 2001; Kim et al, 2004; Hoster et al,
2008). A C-index of 0Æ5 indicates that outcomes are completely
random, whereas a C-index of 1 indicates that the model is a
perfect predictor. We used the bootstrap procedure as
implemented in the ‘validate’ functions of the Design library
in R (R Development Team 2009), which allowed for
computation of an unbiased estimate of the C-index. We used
500 bootstrap samples. To identify MCR with an independent
DLBCL Subgroups and Genomic Aberrations
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impact on survival, we used a Cox proportional-hazard model
with a stepwise selection of the significant variables. MCR
occurring in at least 5% of the patients and with a significant
impact in univariate analysis, and the single factors of the
International Prognostic Index (IPI) for aggressive lymphomas
were included in the model. A P-value below 0Æ05 was
considered as statistically significant. Chi-square test was used
to compare differences in clinical parameters among the
different NMF subgroups previously identified. Statistical
analyses on clinical data were performed with spss 17Æ0Æ1
(SPSS, Chicago, IL, USA) and R statistical package (R
Development Team 2009).
Results
The frequencies of gains, losses and of LOH in 166 DLBCL
samples are shown in Fig 1. The following MCRs were
identified: 58 gains, 47 losses, 54 LOH, five recurrent
amplifications and seven homozygous deletions (Table SI).
Amplifications occurred at 2p16Æ1 (7/166, 4%), 2p15 (3/166,
2%), 9p24Æ3–p21Æ3 (3/166, 2%), 13q32Æ1 (2/166, 1%) and
19q13Æ3 (2/166, 1%). Known oncogenes and lymphoma genes
were present in 3/5 lesions: BCL11A and REL (2p16), JAK2
(9p), SPIB (19q). The 2p15 included C2orf86, MDH1, UGP2.
The 13q32Æ1 region contained DNAJC3, HS6ST3, OXGR1,
UGGT2 and mapped approximately 4 Mb telomeric to the
transforming MIR17-92 cluster.
Homozygous deletions occurred at 3p14Æ2 (2/166, 1%),
6q23Æ3–q24Æ1 (2/166, 1%), 9p21Æ3 (5/166, 3%), 10q23Æ31 (2/
166, 1%), 14q11Æ2 (3/166, 2%), 15q11Æ2 (2/166, 1%), and
19p13Æ3–p13Æ2 (2/166, 1%). Known tumour suppressor genes
were included in 4/7 of these these MCRs: FHIT (3p14Æ2),
TNFAIP3 (A20) (6q23Æ3), CDKN2A (9p21Æ3) and FAS
(10q23Æ31). The 14q and 15q might be considered bona fide
CNV because they had a total overlap with known CNV,
although the first lesion is located within the T-cell receptor
alpha locus (TRA@), and could be due to infiltrating normal
T-cells or a T-cell rearrangement that occurred in the
lymphoma B-cell (Fuschiotti et al, 2007). The 15q deletion
targeted OR4N4 and OR4M2, G-protein-coupled receptors,
members of the olfactory receptor gene family. The deletion of
the 19p13 region has not been previously reported and
comprised a series of genes, including C3 (complement
precursor 3), TNFSF9 and TNFSF14 (tumour necrosis factor
ligand superfamily nine and 14).
Genomic regions and outcome in patients treated with
R-CHOP-21
Table I shows the clinical features of 124/166 (75%) cases,
treated with R-CHOP-21 and for whom follow-up data were
available.
The rate of complete remissions (CR) was 81% (100/124),
partial remissions (PR) 12% (15/124) and stable (SD) or
progressive disease (PD) 7% (9/124). Among the complete
responders, 27 (22%) eventually relapsed. After a median
follow-up of 23 months (range, 1–123 months), the 3-year
estimated OS was 88%, PFS 65% and DFS 71%.
Figure S2 shows the frequency of CN changes and of LOH
for the 100 patients who obtained a CR after R-CHOP-21 and
for the 24 who did not. The following lesions were more
frequent in the non-CR patients: del(8p) (21% vs. 5%;
P = 0Æ023), del(8p21Æ2–p23Æ1) (21% vs. 6%; P = 0Æ036),
del(15q11Æ2) (8% vs. 0%; P = 0Æ036) and LOH of 8p23Æ1
Fig 1. Frequency of DNA gains (red) and losses (blue) (upper panel) and LOH (lower panel), at observed in 166 DLBCL samples. X-axis,
chromosome localization and physical mapping; Y-axis, percentage of cases showing the aberrations.
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(25% vs. 4%; P = 0Æ003), 9p (12Æ5% vs. 2/100, 2%; P = 0Æ049)
and 15q21Æ3 (22% vs. 5%; P = 0Æ019) (Table SI).
Twenty regions showed a statistically significant impact on
OS, PFS and/or DFS (Table II).
Lesions with the strongest association with a worse outcome
were deletions affecting the short arm of chromosome 8:
del(8p23Æ1) (P = 0Æ002, Fig 2), del(8p) (P = 0Æ01), and
del(8p23Æ1–21Æ2) (P = 0Æ012). The prognostic relevance of these
aberrations was underlined by an internal validation which
calculated the C-index corrected for over-fitting by a bootstrap
procedure. The C-index values were 0Æ64, and 0Æ584, 0Æ58.
Among the four homozygous deletions associated with a
poor clinical outcome, two targeted known tumour suppressor
genes: TNFAIP3 at 6q23Æ3, and FAS at 10q23Æ31. Two, at
14q11Æ2 and 15q11Æ2, occurred at bona fide CNV: TRA@ and
OR4N4/OR4M2 respectively). Although statistically significant,
there were only a few cases bearing the four recurrent
homozygous deletions, making it impossible to ascertain their
real impact on outcome.
In order to identify possible pathways affected by these
genomic regions, we mapped the genes contained within
MCRs to known biological pathways. Seven pathways
appeared to be significantly enriched: natural killer cell-
mediated cytotoxicity, regulation of autophagy, antigen
processing and presentation, Jak-STAT signalling pathway,
Toll-like receptor signalling pathway, cytokine-cytokine recep-
tor interaction and apoptosis (Table III).
In order to evaluate whether the identified MCRs were
independent prognostic factors for OS, PFS and DFS, we
performed a multivariate Cox regression. From the IPI factors,
only lactate dehydrogenase (OS, P = 0Æ032 and PFS,
P = 0Æ002) and stage III/IV (PFS, P = 0Æ017) influenced
survival independently in the multivariate analysis. None of
the regions retained significance in the multivariate analysis.
Lesions associated with del(8p23Æ1)
We compared the pattern of genomic aberrations in patients
with and without del(8p23Æ1) to elucidate the possible biolog-
ical significance of genomic losses at this locus. Cases with
del(8p23Æ1) presented several associated lesions (Table SII).
The highest statistical significance was observed for losses
occurring on the long arm of chromosome 15 (50% vs. 10%;
P = 0Æ00004), on 17p (41% vs. 10%; P = 0Æ0006), on 10q23Æ33–
q24Æ1 (32%, vs. 7%; P = 0Æ002) and for 11q gains (41%, vs.
11%; P = 0Æ0009).
Unsupervised clustering
In order to identify subgroups of patients with different genetic
lesions and with possible distinct clinical outcome, we
performed unsupervised clustering using the NMF algorithm.
The latter represents a relatively new algorithm, showing
advantages in the analysis of arrayCGH over other unsuper-
vised approaches (Chigrinova et al, 2010). Five clusters were
identified with distinct genetic profiles (Figs 3, and S3),
without a significant bias on geographic provenance. Cluster
1 consisted of 77/166 patients (46%). Their genetic profile was
heterogeneous and few recurrent aberrations could be
Table I. Clinical characteristics of 124 DLBCL patients treated with
R-CHOP.
Clinical characteristics n Valid Percent
Median age, years (range) 64 (18–86)
Sex (m:f) 58:63 121 48:52
PS > 1 24 119 20
LDH > normal 62 110 57
Extranodal sites > 1 24 115 24
Stage III/IV 80 122 66
Bulky disease > 10 cm 24 109 22
IPI score > 1 77 103 75
B-Symptoms 40 119 34
Beta2-MG > normal 24 43 56
Germinal centre B-cell like* 48 78 55
HCV infection 10 76 13
Only extranodal disease 15 104 14
BM involvement 21 111 20
PS, performance status; LDH, lactate dehydrogenase IPI, International
Prognostic Index; HCV, hepatitis C virus; BM, bone marrow.
*assessed by GEP or by immunohistochemistry. *assessed by GEP in 34
and by immunohistochemistry in 44 cases.
Table II. Twenty regions with a statistical significant impact on OS,
PFS and/or DFS.
Region
OS
P-value/
Q-value
PFS
P-value/
Q-value
DFS
P-value/
Q-value
1q42Æ2 LOH* 0Æ007/n.s. <0Æ001/<0Æ001 0Æ034/n.s.
del(4p12–11) n.s. n.s. 0Æ028/n.s.
4q32Æ2 LOH* n.s. n.s. 0Æ045/n.s.
6q24Æ1–q24Æ2 LOH n.s. 0Æ021/n.s. n.s.
6q23Æ3–q24Æ1 hdel* 0Æ035/n.s. n.s. n.s.
6q22Æ32–q22Æ33 LOH n.s. n.s. 0Æ003/n.s.
6q25Æ1 LOH* n.s. n.s. 0Æ007/n.s.
8p23Æ1 LOH 0Æ015/n.s. n.s. n.s.
del(8p23Æ1) 0Æ002/0Æ1 n.s. n.s.
del(8p23Æ1–21Æ2) 0Æ012/n.s. n.s. n.s.
del(8p) 0Æ01/n.s. n.s. n.s.
9p21Æ1 LOH n.s. 0Æ047/n.s. n.s.
del(9p24Æ2) 0Æ047/n.s. n.s. n.s.
9q31Æ1 LOH 0Æ04/n.s. n.s. n.s.
9p24Æ3–p21Æ3 ampl* n.s. n.s. <0Æ001/0Æ001
10q23Æ31 hdel* <0Æ001/<0Æ001 <0Æ001/<0Æ001 n.s.
14q11Æ2 hdel* n.s. n.s. 0Æ001/0Æ077
15q11Æ2 hdel* <0Æ001/<0Æ001 <0Æ001/0Æ001 n.s.
del(15q12–21Æ2) 0Æ034/n.s. n.s. n.s.
del(18p11Æ32) n.s. 0Æ027/n.s. n.s.
*£5 patients with the genomic alteration. hdel, homozygous deletion;
ampl, amplification. n.s., >0Æ05 for P-value, >0Æ5 for Q-value.
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observed. The second group (Cluster 2) was represented by 28/
166 patients (17%) and characterized by gain of 1q and 3q, as
well as loss of 1p, 6q and 17p. The third group included 8/166
patients (4%), with gains of 2p, 11p and 11q and losses of 1p,
6q, 9p, 15q, 17p and 18p. The fourth group consisted of 38/166
patients (23%). Their genetic profile showed gains of 1q, 2p,
6p, 7, 12q and losses of 6q, 8p, 15q and 17p. Finally, the fifth
group was represented by 15/166 patients (9%). It was
characterized by gains of 3q, 11q, 13q, 18q and losses of 1p,
6q, 8p, 9p and 15q.
Due to the distinct genomic profiles we compared Cluster 1
versus Clusters 2 and 4 and Cluster 2 versus Cluster 4. Cluster 1
showed a lower percentage of older patients (P = 0Æ068), a
significantly higher rate of bone marrow (BM) involvement
(16/57, 28% vs. 1/19, 5% and 2/24, 8%; P = 0Æ008) and
hepatitis C virus (HCV) infection (9/38, 24% vs. 1/12, 8% and
0/20; P = 0Æ014). Clusters 2 and 4 showed differences in the
number of patients with a high IPI-score (9/16, 56% vs. 7/26,
27%; P = 0Æ057), and relapse rate (5/17, 29% vs. 2/25, 8%;
P = 0Æ068). We did not further analyse Clusters 3 and 5
(overall 23 patients).
Cluster 1 was not only characterized by a distinct genomic
profile and different clinical features, such as high HCV
infection and BM involvement, but, similar to Cluster 2, the
outcome was relatively poor when compared to Cluster 4: high
relapse rate (26%), 3-year estimated OS of 83%, 61% PFS and
66% DFS. Moreover, unlike Cluster 2 and 4, the PFS of Cluster
1 did not reach a plateau. The comparison of Cluster 2 and 4
showed a poorer DFS for Cluster two patients (P = 0Æ048).
After 5 years both Clusters 2 and 4 reached a plateau in OS,
PFS and DFS. In Cluster 2, the 3-year estimate of OS was 80%,
PFS 62% and DFS 67%, whereas in Cluster 4, the 3-year
estimate of OS was 92%, PFS 84% and DFS 83% (Fig S4).
The distribution of GCB or activated B-cell like (ABC)
DLBCL, defined by GEP or by immunohistochemistry, did not
present statistical differences among the five NMF clusters,
although Cluster 4 consisted of mainly GCB (8/12, 67%), and
Cluster 5 of ABC (7/10, 70%) (Fig S3). The distribution of the
Fig 2. Del(8p23Æ1) in DLBCL: OS (P = 0Æ002; Panel A) and PFS (P = 0Æ119; Panel B) in patients without and with del(8p23Æ1); Frequency plots of
DNA gains (red) and losses (blue) observed in patients with (22) and without (144) del(8p23Æ1) (Panels C and D).
M. Scandurra et al
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DLBCL-consensus clusters OxPhos, BCR, and HR presented a
statistically significant distribution of HR cases, which were
almost all in NMF Cluster 1 (12/16, 75%; P = 0Æ023) (Fig S3).
A supervised analysis of the gene expression profile of
Cluster 1 versus Clusters 2 and 4 identified 546 probes
(P < 0Æ005) (Table SIII). Genes of the T-cell receptor signalling
pathway were the only significantly over-represented group of
genes (P = 2 E)06; Q = 4 E)04). All 8/166 DLBCL cases
described as T-cell rich were classified as Cluster 1.
Fig S5 shows the pattern of genomic lesions in 98 cases
according to HCV-status. Although no statistical significance
could be demonstrated, the 12 HCV+ DLBCL cases appeared
to have less recurrent aberrations than HCV-negative cases, in
accordance with that observed in NMF clustering.
Discussion
We conducted this retrospective multi-centre study to explore
the impact of unbalanced genomic aberrations, detected using
a high-density genome wide-SNP-based array, on OS, PFS and
DFS in a population of DLBCL patients treated with the
standard regimen R-CHOP-21. Deletions affecting the short
arm of chromosome 8 had the most significant impact on
survival. Five subgroups of patients with different aberrations
and clinical features were identified by unsupervised clustering.
A series of 171 recurrent lesions were identified, largely
reflecting what has already been reported in DLBCL (Tagawa
et al, 2005a; Lenz et al, 2008a; Lenz & Staudt, 2010). The high
resolution of the arrays allowed the detection of a discrete
number of recurrent homozygous deletions, some targeting
well known tumour suppressor genes, such as CDKN2A (9p21)
or FAS (10q23Æ31), and the more recently reported TNFAIP3
(Compagno et al, 2009). A homozygous deletion affected
19p13, possibly overlapping that reported in mantle cell
lymphoma (Tagawa et al, 2005b). The lesion was still relatively
large in size with several genes as possible targets, including C3,
TNFSF9 and TNFSF14.
Twenty regions revealed a significant correlation with
clinical outcome. In order to exclude a selection bias, we
compared the observed clinical parameters to a previously
published series of patients affected by DLBCL (Sehn et al,
2005), showing that they were comparable and thus reflected
the general population of DLBCL patients. Loss of genomic
material in the short arm of chromosome 8, in particular at
8p23Æ1, was associated with the most significant impact on OS,
also confirmed by an internal validation by bootstrap.
Moreover, the same region was more common among non
responders. Del(8p) and loss of smaller regions of this
chromosome arm were previously shown to be associated
with poor characteristics and worse outcome in other
lymphoid neoplasms (Martinez-Climent et al, 2001; Rubio-
Moscardo et al, 2005a; Thelander et al, 2005; Forconi et al,
2008). Losses of 17p (TP53, HIC1) and 15q (TP53BP1) were
observed at a statistically higher prevalence in association with
loss of 8p, suggesting that the possible poor outcome after
R-CHOP-21 could be due to the concomitant deregulation of
a series of genes mapped on different chromosomes. Indeed,
genes involved in DNA repair and apoptosis are mapped in
these regions and could all be inactivated in patients bearing
these deletions: TNFRSF10A (TRAIL-R1) and TNFRSF10B
(TRAIL-R2) (8p), TP53 and HIC1 (17p) and TP53BP1 (15q)
(Rubio-Moscardo et al, 2005b; Young et al, 2007; Takeyama
et al, 2008), which are enriched among patients with a poor
CR-rate. Interestingly, in DLBCL, loss of TP53 has been shown
Table III. Significantly enriched pathways among the MCRs with an impact on OS, PFS and DFS.
Pathway Genes P-value Benjamini
Apoptosis CHP, TNFRSF10C, FAS, PPP3CC, TNFRSF10B, TNFRSF10A,
TNFRSF10D,
0Æ011 0Æ273
Natural killer cell mediated cytotoxicity CHP, IFNB1, IFNA6, IFNA8, SHC4, IFNA21, PPP3CC,
TNFRSF10B, IFNA7, IFNA17, IFNA2, IFNA16, IFNA5,
TNFRSF10C, IFNA4, FAS, IFNA1, IFNA10, TNFRSF10A, IFNA14,
TNFRSF10D,
2Æ98 · 10)12 6 · 10)10
Regulation of autophagy IFNA6, IFNA4, IFNA8, IFNA21, IFNA1, IFNA10, IFNA7, IFNA17,
IFNA14, IFNA5, IFNA16, IFNA2
1Æ05 · 10)11 1Æ06 · 10)9
Jak-STAT signalling pathway IFNA6, IFNB1, IFNA8, IFNA21, JAK2, IFNA17, IFNA7, IFNA2,
IFNW1, IFNA16, IFNA5, SPRED1, IFNA4, IFNA1, IFNA10,
IFNA14
1Æ04 · 10)6 5Æ24 · 10)5
Toll-like receptor signalling pathway IFNA6, IFNB1, IFNA8, IFNA21, IFNA17, IFNA7, IFNA2, IFNA16,
IFNA5, IFNA4, IFNA1, IFNA10, IFNA14
2Æ17 · 10)6 8Æ73 · 10)5
Antigen processing and presentation IFNA6, IFNA8, IFNA21, PDIA3, CTSB, IFNA17, IFNA7, IFNA2,
IFNA16, IFNA5, IFNA4, IFNA1, IFNA10, B2M, IFNA14
1Æ48 · 10)9 9Æ91 · 10)8
Cytokine-cytokine receptor interaction IFNB1, IFNA6, IFNA8, IFNA21, TNFRSF10B, IFNA7, IFNA17,
IFNA2, IFNW1, IFNA16, IFNA5, TNFRSF10C, IFNA4, FAS,
IFNA1, IFNA10, TNFRSF10A, IFNA14, TNFRSF10D
1Æ12 · 10)5 3Æ76 · 10)4
For each pathway, genes mapped in the MCRs, and the level of statistical enrichment (P-value and Benjamini-multiple test corrected) are given.
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to correlate with low levels of TNFRSF10B (Young et al, 2007),
and loss of 8p is a frequent phenomenon in patients with
chronic lymphocytic leukaemia with 17p loss, possibly iden-
tifying a subgroup of patients with an extremely poor outcome
(Forconi et al, 2008). Regarding TP53, in our series, loss of
17p13Æ1 did not show any impact on the clinical outcome,
Fig 3. Frequency plot of 166 patients showing gains and losses according to the different NMF clusters. 3a: Cluster 1, 3b: Cluster 2, 3c: Cluster 3, 3d:
Cluster 4, 3e: Cluster 5. X-axis, chromosome localization and physical mapping; Y-axis, percentage of cases showing the aberrations.
M. Scandurra et al
228 ª 2010 Blackwell Publishing Ltd, British Journal of Haematology, 151, 221–231
similarly to that previously reported by Young et al (2007),
who showed a negative influence of TP53 mutations but not of
the genomic loss on the clinical course in their series of DLBCL
patients.
Del(9p21Æ3) had a negative impact on the response to
treatment, albeit no apparent influence on survival was
observed. These results are consistent with previous data
reporting the unfavourable influence of this aberration on
CHOP-treated DLBCL patients (Lenz et al, 2008a).
Functional annotation analysis and pathway mapping iden-
tified seven significantly enriched pathways among the genes of
the regions with an impact on survival. Among the genes
involved in these pathways were TNFRST10A/TNFRSF10B,
FAS (natural killer mediated cytotoxicity and apoptosis) and
JAK2 (JAK-STAT pathway). Both, TNFRST10A/TNFRSF10B
and FAS are genes coding for proteins with a crucial role in
regulation of cell death and are known to be involved in
mechanisms of tumour escape (Khong & Restifo, 2002).
Therefore, loss of these genes in DLBCL strengthens the notion
that both genes may play an important role in this disease. On
the contrary, JAK2, a gene coding for a protein able to promote
cell transformation by constitutive activation of the JAK-STAT
pathway (Knoops et al, 2008), was amplified. The specific role
of this aberration in DLBCL is yet unclear, whereas it has been
shown that JAK2 genomic gains are frequent in primary
mediastinal large B-cell lymphoma and Hodgkin lymphoma,
but they can occur also in DLBCL, more commonly among
ABC-type (Lenz et al, 2008a).
The relatively small number of cases bearing the lesions and
the median follow-up of only 2 years might partially explain
the fact that none of the 20 genomic markers remained as an
independent prognostic marker when analysed in a multivar-
iate analysis alongside the IPI factors.
The unsupervised NMF-clustering identified five clusters
with distinct genetic profiles, and some with different clinical
characteristics and distinct courses.
Cluster one patients were characterized by a heterogeneous
genomic profile, lacking most recurrent lesions and displaying
the worst long term outcome amongst the different clusters.
These patients had a high rate of HCV infection and BM
involvement and a slightly younger age. GEP and morphology
data suggested that this cluster could represent DLBCL cases
with a high content of normal infiltrating T-cells, which would
partially explain the low rate of recurrent genomic aberrations
due to a lower content of neoplastic cells. These data could
delineate a DLBCL subtype with distinct clinical features and a
high rate of inflammatory cells. Indeed, when we applied the
DLBCL-consensus cluster classifier (Monti et al, 2005) to our
DLBCL cases with available GEP, there was a statistically
significant enrichment of Cluster 1 for HR-DLBCL. The latter
subgroup of DLBCL has been described as having increased
expression of T-cell molecules, and, when compared to other
DLBCL cases, HR patients were significantly younger, had a
higher incidence of BM involvement and a lack of the
recurrent chromosomal translocations involving BCL2 or
BCL6 (Monti et al, 2005). Alternatively, we can speculate that,
as we observed a high prevalence of HCV infection and
because viruses can induce epigenetic transforming changes in
human cells (Ferrari et al, 2009), at least part of Cluster 1
DLBCL, as well of the HR cluster, might have developed
mainly through epigenetic changes rather than genomic
aberrations. In support of this hypothesis, in our series,
HCV-positive DLBCL cases showed a tendency for a lower rate
of genomic lesions, but the number of cases was small and only
studies on micro-dissected lymphoma cells will provide final
results.
Similar to Cluster 1, the outcome of the Cluster two
patients was relatively poor. This subgroup was characterized
by 1q gain, 3q gain, 1p, 6q and 17p losses. Conversely,
Cluster four patients, mainly characterized by gains of
chromosome 7 and 12, presented a good outcome. Among
the remaining two clusters, Cluster 3 was characterized by
losses of 6q, 9, and 11q gains, and a trend for a good
outcome, whilst Cluster 5 (gains of 3q, 11q and 18q; losses of
6q, 8p, 9p, 15q and 17p) for a poor outcome. The
distribution of cases according to the cell-of-origin did not
show statistical differences, probably due to the small
number of cases with GEP, but, as expected based upon
their genomic profiles, Clusters 4 and 5 presented more GCB
and ABC cases, respectively. These data, together with our
previous experience with NMF (Chigrinova et al, 2010), and
the data reported using a model-based clustering (Shah et al,
2009), strongly suggest that the application of new unsuper-
vised clustering algorithm on large DLBCL arrayCGH
datasets will provide important insights for sub-classifying
this heterogeneous disease.
In conclusion, genetic features associated with a different
outcome were identified by genome-wide SNP-based array-
CGH. When confirmed in other series, loss of 8p might
highlight a group of patients with worse outcome when treated
with R-CHOP-21 and characterized by a series of concomitant
additional aberrations such as 17p and 15q losses. By applying
unsupervised clustering, a distinct subgroup of patients
characterized by a heterogeneous genomic profile, high
prevalence of HCV infection, BM involvement and poor
outcome with R-CHOP-21 could be observed. This subgroup
deserves to be better characterized in order to design ad hoc
therapeutic strategies.
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